{"analyses":[{"ciLowerLimit":"-1.1","ciPctValue":"95","ciUpperLimit":"17.5","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.076","paramType":"Difference in Response Rates","paramValue":"8.2","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.2","upperLimit":"56.0","value":"50.6"},{"groupId":"OG001","lowerLimit":"35.0","upperLimit":"50.0","value":"42.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"177"}],"units":"Participants"}],"description":"Tumor response was assessed per criteria published by Cheson et al (1999). According to consensus recommendations, CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by greater than (\\>) 75 percent (%) but still \\>1.5 centimeters (cm) in size, and indeterminate bone marrow assessment. The percentage of participants with either response at the end of induction (EOI) was determined with corresponding 95% Pearson-Clopper confidence interval (CI).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For Cycle 1, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion; subsequent doses were given as 1400 mg via SC injection. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG000","title":"Rituximab SC"},{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For all cycles, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG001","title":"Rituximab IV"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat (ITT) Population: All participants who completed Baseline and at least one on-treatment efficacy assessment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4.25 years","title":"Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}